LAUSR

Dolutegravir (DTG) is a second‐generation integrase strand transfer inhibitor that is recommended by the World Health Organization as the preferred first‐line and second‐line antiretroviral therapy (ART) in patients with HIV. In 2018, Uganda started using DTG‐based regimens as the preferred first‐line ART. However, concerns regarding the potential neurotoxicity of DTG have been increasing. Data on the occurrence of neuropsychiatric adverse events (NPAEs) and the associated factors among adult patients who are initiated on or switched to DTG‐based first‐line or second‐line ART in Uganda are limited.